New drug targets DNA repair to fight Hard-to-Treat blood cancers
NCT ID NCT03770429
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a drug called AZD6738 in 52 people with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease got worse after standard therapy. The drug works by blocking a DNA repair pathway that cancer cells rely on, causing them to die while sparing healthy cells. The main goal is to check safety and find the right dose, with a secondary look at whether it can shrink or control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD6738 (a drug that blocks a DNA repair pathway to kill cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with MDS or CMML whose disease has stopped responding to standard therapy.
What could go wrong
This is a very early (Phase 1) trial with only 52 participants, so it's mainly checking safety. It may not prove effective, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BIDMC
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02215, United States
-
Washington University
St Louis, Missouri, 63110, United States